ETFs To Buy On Solid Biotech Stock Earnings [Celgene Corporation, Biogen Idec Inc, Alexion Pharmaceuticals, Inc., Amgen, Inc.]

Gilead, Amgen, Celgene and Biogen occupy the top four spots in the fund, with a combined exposure of 45%. The fund has returned 27.6% this year and charges 35 basis points as expenses. BBH currently has a Zacks ETF Rank #1 or Strong Buy rating.


This fund follows the S&P Biotechnology Select Industry Index and holds about 84 securities in its basket. It is quite well spread out across its components with none of the stocks having more than 2.5% allocation. In fact, Gilead, Biogen Celgene, Alexion and Amgen have a combined 7% allocation.

The ETF puts more focus on small- and micro-cap stocks at 76%, while mid and large caps account for the rest. The product has nearly $1.3 billion in AUM and sees solid volume of 383,000 shares per day. It charges 35 bps in annual fees and has returned 30% this year. XBI currently carries a Zacks ETF Rank #2 or Buy rating.

This article is brought to you courtesy of Zacks.

Pages: 1 2

Leave a Reply

Your email address will not be published. Required fields are marked *